Cara Therapeutics Readies Novel Analgesic For Phase III In Acute Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Having just completed an IPO netting nearly $59 million, Cara is seeking an end-of-Phase II meeting with FDA to design registrational trials for CR845, an intravenous selective kappa opioid receptor agonist in post-surgical pain. It also plans a Phase I trial for an oral tablet formulation of ‘845 to address the outpatient setting.